Clinical trials: Microangiopathy
Thrombotic Micro-angiopathy
Therapeutic Orientation Test in Thrombotic Microangiopathy
Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich block alternative complement pathway…
- Trial name
- TOTEM (NCT04777435)
- Testing
- Therapeutic orientation test for TMA
- Where
- 20 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT05855083
- Testing
- Biological: narsoplimab
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Omeros Corporation
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Transplant Associated Microangiopathy TAM
Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
This was a randomized, SoC-controlled, open-label, multi-center study in patients with TAM after hematopoietic precursor cell transplantation (HPCT) .
- Trial name
- NCT02763644
- Testing
- LFG316 active drug, Standard of care treatment
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Pre-Eclampsia, Severe, HELLP Syndrome
Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome
Immature platelet fraction is a non-invasive test of real time thrombopoiesis. High IPF% has been suggested as an indicator of thrombocytopenia due to rapid platelet consumption.
- Conditions
- Pre-Eclampsia, Severe, HELLP Syndrome, Microangiopathy
- Trial name
- NCT03232359
- Testing
- immature platelets fraction
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- AYMAN ABDELKADER MOHAMED ABDELKADER
Microangiopathy, Kidney Transplant
Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant Centre
It is a retrospective-prospective, single-centre, non-pharmacological, retrospective tissue study carried out for scientific and health protection purposes.
- Trial name
- PT-TMA2022 (NCT06759961)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Stem Cell Transplant Complications, Thrombotic Microangiopathies
Study in Adult and Pediatric Patients With HSCT-TMA
This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement…
- Trial name
- NCT04970004
- Testing
- No intervention
- Where
- United States
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathy, Hemolytic Uremic Syndrome
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy
- Conditions
- Thrombotic Microangiopathy, Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
- Trial name
- NCT00593229
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Coronary Artery Disease
Single Blind Randomized Study to Determine the Sensitivity and Specificity of 2 Non-invasive Markers of Early Coronary Disease
Diagonal ear lobe crease and microcirculatory disorder in the conjunctiva are both non invasive methods documented in the literature as early signs of coronary artery disease.
- Trial name
- NCT01742156
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
TTP - Thrombotic Thrombocytopenic Purpura
Italian iTTP Registry
ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients…
- Trial name
- NCT06376786
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione Luigi Villa
aHUS - Atypical Hemolytic Uremic Syndrome
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.
- Trial name
- NCT05684159
- Testing
- NM8074
- Volunteers
- 12 people
- Sponsor
- NovelMed Therapeutics
Microangiopathy, Diabetic, Polyphenol
Macro- and Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes
The greatest challenge in our ageing society are cardiovascular diseases such as stroke, heart attack, peripheral artery disease of the legs with non-healing wounds (ulcers), or diabetes.
- Conditions
- Microangiopathy, Diabetic, Polyphenol, Optical Tomography, Vascular Endothelium
- Trial name
- NCT05449782
- Testing
- Cocoa flavanol
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
This phase II trial tests how well defibrotide works in preventing transplant-associated thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing tandem transplants (hematopoietic stem cell…
- Conditions
- Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma, High-risk Neuroblastoma, Thrombotic Microangiopathies
- Trial name
- NCT06182410
- Testing
- Defibrotide
- Sponsor
- University of California, San Francisco
Thrombotic Microangiopathies
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy
- Trial name
- NCT04784455
- Testing
- nomacopan (rVA576)
- Where
- 9 sites in United States, Poland and 1 more
- Volunteers
- 10 people
- Sponsor
- AKARI Therapeutics
Thrombotic Microangiopathies, Hematologic Diseases
A Safety and Efficacy Study of NAC in Patients With TA-TMA
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement…
- Trial name
- NCT03252925
- Testing
- N-Acetylcysteine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Atypical Hemolytic Uremic Syndrome
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
- Trial name
- APPELHUS (NCT04889430)
- Testing
- Iptacopan
- Where
- 36 sites in United States, Brazil and 6 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Complications in AIDS Patients, Such as Fundus Opportunistic Infections, Microangiopathy, and Uveitis
Analysis of Ocular Complications of AIDS Patients in Ophthalmic Consultation
Through a cross-sectional descriptive analysis of ophthalmic consultation of AIDS patients in the past 3 years, the basic characteristics of patients were described according to whether there was fundus change, and the clinical…
- Trial name
- NCT06250881
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhongnan Hospital
Thrombotic Microangiopathy
Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients
Thrombotic Microangiopathy (TMA) Associated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a serious complication that is associated with increased morbidity, related to multiple organ failure, with increased…
- Trial name
- NCT07059026
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- ITAC (Instituto de Trasplantes y Alta Complejidad)
Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
TGD001 Treatment in Thrombotic Microangiopathies
This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or…
- Trial name
- NCT07459114
- Testing
- TGD001
- Volunteers
- 70 people
- Sponsor
- TargED Biopharmaceuticals B.V.